Cargando…

Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer

SIMPLE SUMMARY: The development of several antiHuman Epidermal Growth Factor Receptor 2 (HER2) treatments over the last few years has improved the landscape of HER2-positive breast cancer. Despite this, relapse is still the main issue in HER2-positive breast cancer. The reasons for therapeutic failu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrando-Díez, Angelica, Felip, Eudald, Pous, Anna, Bergamino Sirven, Milana, Margelí, Mireia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320771/ https://www.ncbi.nlm.nih.gov/pubmed/35884366 http://dx.doi.org/10.3390/cancers14143305

Ejemplares similares

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

Targeted therapeutic options and future perspectives for HER2-positive breast cancer
por: Wang, Jiani, et al.
Publicado: (2019)

Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data
por: Bernat-Peguera, Adrià, et al.
Publicado: (2022)

Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients
por: Hardy-Werbin, Max, et al.
Publicado: (2019)

Lights and Shadows in Immuno-Oncology Drug Development
por: Bergamino Sirvén, Milana, et al.
Publicado: (2021)

Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer
por: Pons, Laura, et al.
Publicado: (2023)

Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
por: Sirvén, Milana Bergamino, et al.
Publicado: (2019)

When Standard Therapy Fails in Breast Cancer: Current and Future Options for HER2-Positive Disease
por: Olson, Erin, et al.
Publicado: (2013)

HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies
por: Pous, Anna, et al.
Publicado: (2023)

Neratinib for HER2-positive breast cancer with an overlooked option
por: Guo, Liting, et al.
Publicado: (2023)

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
por: Krasniqi, E., et al.
Publicado: (2019)

Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
por: Agostinetto, Elisa, et al.
Publicado: (2022)

Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer
por: Pons, Laura, et al.
Publicado: (2022)

Current neoadjuvant treatment options for HER2-positive breast cancer
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

The Future of HSR Program Evaluation: A European Perspective
por: Sirven, N, et al.
Publicado: (2023)

Future therapeutic options
por: Reuser, Arnold
Publicado: (2013)

The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs
por: Cook, Nigel, et al.
Publicado: (2019)

Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer
por: Vila, Mireia Margelí, et al.
Publicado: (2020)

SAMHD1 expression modulates innate immune activation and correlates with ovarian cancer prognosis
por: Gutiérrez-Chamorro, Lucía, et al.
Publicado: (2023)

Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections
por: Vrancianu, Corneliu Ovidiu, et al.
Publicado: (2021)

Pyrotinib as a therapeutic for HER2-positive breast cancer
por: Kioutchoukova, Ivelina, et al.
Publicado: (2023)

Targeting HER2-positive breast cancer: advances and future directions
por: Swain, Sandra M., et al.
Publicado: (2022)

PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution
por: Pernas, Sonia, et al.
Publicado: (2019)

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
por: Bergamino, Milana A., et al.
Publicado: (2022)

Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives
por: Sarkar, Chandan, et al.
Publicado: (2020)

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer
por: Chien, A. Jo, et al.
Publicado: (2012)

Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
por: Corti, C., et al.
Publicado: (2021)

Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution
por: Pernas, Sonia, et al.
Publicado: (2019)

Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy
por: Castellví, Marc, et al.
Publicado: (2020)

Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer
por: Pallerla, Sandeep, et al.
Publicado: (2021)

Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis
por: Papadimitriou, Theodoros-Ioannis, et al.
Publicado: (2022)

Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer—Current Treatment Options and Future Perspectives
por: Koustas, Evangelos, et al.
Publicado: (2022)

Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options
por: Gampenrieder, Simon Peter, et al.
Publicado: (2020)

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
por: Lefort, S, et al.
Publicado: (2017)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni, Mohamad Adham, et al.
Publicado: (2021)

Treatment of toxoplasmosis: Current options and future perspectives
por: Konstantinovic, Neda, et al.
Publicado: (2019)

Current Options and Future Perspectives in the Treatment of Dyslipidemia
por: Muscoli, Saverio, et al.
Publicado: (2022)

Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
por: Vega Cano, Kreina Sharela, et al.
Publicado: (2022)

Therapeutic siRNA for drug-resistant HER2-positive breast cancer
por: Gu, Shenda, et al.
Publicado: (2016)

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
por: Pernas, Sonia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3ub655ekfai3976gflon1pp7lu